Patch Testing Ingredients of Dermabond and Other Cyanoacrylate-Containing Adhesives.

CONCLUSIONS: Octyl cyanoacrylate is the usual allergenic ingredient in Dermabond. Patch testing with high concentrations is often required. Testing Dermabond on abraded skin further improves diagnostic sensitivity by more closely simulating clinical use. PMID: 31517667 [PubMed - as supplied by publisher]
Source: Dermatitis - Category: Dermatology Authors: Tags: Dermatitis Source Type: research

Related Links:

This study discovered a novel neuro-epidermal BNP-TRPV3-Serpin E1-mediated pathway in severe atopic dermatitis (AD). Serpin E1 was identified as a new itch-inducer. We propose this pathway represents an important target for the treatment of AD.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
This study sought to identify AD endotypes based on allergen sensitization, S. aureus reactivity, and inflammatory signature. The study included 76 adults with moderate to severe AD and 39 healthy controls. All underwent serologic assessment of total IgE and allergen-specific antibodies to a wide range of environmental and food allergens, as well as antibodies against S.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: From the Pages of AllergyWatch Source Type: research
Publication date: Available online 2 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Lise Gehrt, Andreas Rieckmann, Nicholas Kiraly, Aksel Karl Georg Jensen, Peter Aaby, Christine Stabell Benn, Signe Sørup
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Biologics have revolutionized medical therapy in the past 2 decades. Allergic Diseases have benefited from this revolution as a variety of biologics have impacted all categories of allergic diseases. Anticytokines directed at type 2 immunity has helped in the treatment of all allergic conditions covered in this issue ranging from Allergic Rhinitis to Asthma to Atopic Dermatitis to Food Allergy and others. Obviously, the ravages of COVID-19 on processes involved in biologic treatment are a consideration, but current thinking suggests such therapies should not be affected by the pandemic.
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Authors: Tags: Preface Source Type: research
Most immune genes formed a severity-dependent expression gradient in lesional/non-lesional AD. Mild/limited AD lacked the systemic abnormalities characteristic of moderate-to-severe disease, with minimal immune activation in non-lesional skin and blood.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
This study identifies S. aureus derived Sbi as a key virulence factor, capable of triggering type 2 immune responses in vitro and in vivo.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
CONCLUSION: Atopic disorders, previously recognized as predictors of poor sleep, are associated with COPCs after accounting for sleep problems. PMID: 32975542 [PubMed - as supplied by publisher]
Source: Journal of Orofacial Pain - Category: ENT & OMF Tags: J Oral Facial Pain Headache Source Type: research
CONCLUSIONS: Our study suggests that in BPS patients' families, fibromyalgia and autoimmune diseases including asthma, and especially the non-allergic form of asthma, may be over-represented. PMID: 32964777 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
CONCLUSION: Studies on the pattern of allergic sensitization to a specific population offer tools for the more effectual prevention, diagnosis, and treatment of allergic diseases. Sensitization to dust mites house was the most prevalent in the evaluated sample. High rates of sensitization to furry animals also stand out. Patients with food allergy, atopic dermatitis, or multimorbidity appear to be at greater risk for developing more severe allergic diseases. PMID: 32986999 [PubMed - as supplied by publisher]
Source: Jornal de Pediatria - Category: Pediatrics Authors: Tags: J Pediatr (Rio J) Source Type: research
Baricitinib (Olumiant) would be the first JAK inhibitor (and oral medicine) indicated for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.International Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Alert Source Type: news
More News: Allergy | Allergy & Immunology | Chloride | Dermatitis | Dermatology | Skin | Study